$599

Viking Initiates Oral VK2735 Maintenance Study and the CCO Shares Departure

Two cardiometabolic-related news items have been observed: Viking Therapeutics initiated its Ph1 oral VK2735 maintenance study (view press release), and Viking’s CCO announced his departure via LinkedIn (view post). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here